Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 30 Apr 2017
At a glance
- Drugs Anastrozole (Primary) ; Bevacizumab; Erlotinib; Everolimus; Fulvestrant; Sorafenib
- Indications Solid tumours
- Focus Adverse reactions
- 27 Apr 2016 Status changed from recruiting to active, no longer recruiting.
- 08 Feb 2016 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 14 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.